AI companies such as OpenAI and Anthropic have long focused on building tools that can write code that will speed up software ...

Shanda Group has entered a period of renewed visibility, with a series of incubated ventures coming to light over the past several months. At the center of this momentum is its founder, Tianqiao Chen, ...

C compiler, LustreC, into a generator of both executable code and associated specification. Model-based design tools are ...

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

Have you been harmed by a social media algorithm? If so, U.S. Sen. John Curtis wants to let you sue. The Algorithm Accountability Act, introduced Tuesday by Curtis and co-sponsored by Arizona Democrat ...

Posts from this topic will be added to your daily email digest and your homepage feed. A new bill would hold social media platforms responsible for foreseeable algorithmic harms. A new bill would hold ...

Recursion Pharmaceuticals, Inc. leverages AI to accelerate drug discovery, offering both a licensing platform and an internal drug development pipeline. RXRX faces heavy competition, ongoing operating ...

After 12 years leading Utah-based techbio company Recursion, CEO Chris Gibson is stepping down. Recursion’s R&D head and Chief Commercial Officer Najat Khan will become CEO effective Jan. 1. Gibson co ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...